Viropharma, Inc. (VPHM) Tops Q3 EPS by 23c; Guides FY11 Cinryze Net Sales

October 27, 2011 7:39 AM EDT
Viropharma, Inc. (NASDAQ: VPHM) reported Q3 EPS of $0.56, $0.23 better than the analyst estimate of $0.33. Revenue for the quarter came in at $143 million versus the consensus estimate of $129.47 million.

Sees FY11 Cinryze net sales to be between $250 and $260 million.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance